Bristol-Myers Squibb and AstraZeneca have revealed the results from Phase 3 clinical research that investigated the effects of dapagliflozin on blood sugar levels.
The study found how the compound helped to create substantial reductions in blood sugar levels when it was added to Sitagliptin (a DPP4 inhibitor) in patients with Type 2 diabetes at the 24-week juncture.
Serge Jabbour, managing director and division director of endocrinology at Thomas Jefferson University commented on the findings, noting that they add to experts' understanding of dapagliflozin.
"Type 2 diabetes is a complex disease that often requires patients to take multiple treatments to control their blood sugar levels, with DPP4 inhibitors being some of the most widely prescribed therapies," Mr Jabbour explained.
As well as its work alongside AstraZeneca, Bristol-Myers Squibb recently confirmed that it will make up part of the International Immuno-Oncology Network.
The collaboration aims to expand knowledge of immune-oncology, with The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research among the other organisations taking part.